
|Articles|November 1, 2003
Vitrase results presented at retinal society meeting
Irvine, CA -- Two phase III clinical trials of ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals) reveal a statistically significant reduction in vitreous hemorrhage density in patients with diabetes during each of 3 months following a single intravitreous injection of ovine hyaluronidase when compared with a single injection of saline solution.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


